[go: up one dir, main page]

TR200400541T4 - Terapide faydalı tropan türevleri. - Google Patents

Terapide faydalı tropan türevleri.

Info

Publication number
TR200400541T4
TR200400541T4 TR200400541T TR200400541T TR200400541T4 TR 200400541 T4 TR200400541 T4 TR 200400541T4 TR 200400541 T TR200400541 T TR 200400541T TR 200400541 T TR200400541 T TR 200400541T TR 200400541 T4 TR200400541 T4 TR 200400541T4
Authority
TR
Turkey
Prior art keywords
optionally substituted
fluorine atoms
therapy
derivatives useful
tropan
Prior art date
Application number
TR200400541T
Other languages
English (en)
Inventor
Perros Manoussos
Anthony Price David
L. C. Stammen Blanda
Wood Anthony
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0014046A external-priority patent/GB0014046D0/en
Priority claimed from GB0015835A external-priority patent/GB0015835D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR200400541T4 publication Critical patent/TR200400541T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)

Abstract

Mevcut bulus, R1' in istege göre bir veya daha fazla florin atomuyla ikame edilen C3-6 sikloalkil veya istege göre bir veya daha fazla florin atomuyla ikame edilen C1-6 alkil veya istege göre bir veya daha fazla florin atomuyla halka ikamesine tabi tutulan C3-6 sikloalkilmetil oldugu ve R2' nin istege göre bir veya daha fazla florin atomuyla ikame edilen fenil oldugu formül (I) bilesikleriyle, bunlarin farmasötik açidan kabul gören tuzlari ve solvatlariyla ve bu bilesikleri ihtiva eden kompozisyonlarin preparasyonunda kullanilan ara maddelerin preparasyonuna yönelik islemlerle ve bunlarin kullanimlariyla ilgilidir.
TR200400541T 2000-05-26 2001-05-09 Terapide faydalı tropan türevleri. TR200400541T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0014046A GB0014046D0 (en) 2000-05-26 2000-05-26 Compounds useful in therapy
GB0015835A GB0015835D0 (en) 2000-06-27 2000-06-27 Compounds useful in therapy

Publications (1)

Publication Number Publication Date
TR200400541T4 true TR200400541T4 (tr) 2004-04-21

Family

ID=26244452

Family Applications (1)

Application Number Title Priority Date Filing Date
TR200400541T TR200400541T4 (tr) 2000-05-26 2001-05-09 Terapide faydalı tropan türevleri.

Country Status (50)

Country Link
EP (3) EP1990341B1 (tr)
JP (2) JP3693957B2 (tr)
KR (2) KR100548854B1 (tr)
CN (2) CN1279040C (tr)
AP (1) AP1965A (tr)
AR (2) AR028622A1 (tr)
AT (2) ATE260914T1 (tr)
AU (2) AU5248201A (tr)
BG (1) BG65966B1 (tr)
BR (1) BRPI0110955B8 (tr)
CA (1) CA2408909C (tr)
CR (1) CR10145A (tr)
CU (1) CU23288B7 (tr)
CY (3) CY2008006I1 (tr)
CZ (1) CZ299102B6 (tr)
DE (3) DE60102233T2 (tr)
DK (2) DK1526134T3 (tr)
DZ (1) DZ3464A1 (tr)
EA (2) EA007580B1 (tr)
EE (1) EE05110B1 (tr)
EG (1) EG24137A (tr)
ES (3) ES2215129T3 (tr)
FR (1) FR08C0007I2 (tr)
GE (1) GEP20063799B (tr)
HR (1) HRP20020938B1 (tr)
HU (1) HU225810B1 (tr)
IL (2) IL152531A0 (tr)
IS (1) IS2511B (tr)
LT (1) LTC1284974I2 (tr)
LU (1) LU91417I2 (tr)
MA (1) MA26902A1 (tr)
ME (1) ME00555B (tr)
MX (1) MXPA02011631A (tr)
MY (3) MY153023A (tr)
NL (1) NL300338I2 (tr)
NO (3) NO327892B1 (tr)
NZ (1) NZ521477A (tr)
OA (1) OA12264A (tr)
PA (1) PA8517101A1 (tr)
PE (1) PE20011371A1 (tr)
PL (1) PL200551B1 (tr)
PT (2) PT1284974E (tr)
RS (2) RS51436B (tr)
SI (2) SI1284974T1 (tr)
SK (1) SK286129B6 (tr)
TN (1) TNSN01077A1 (tr)
TR (1) TR200400541T4 (tr)
TW (1) TWI230160B (tr)
UY (1) UY26727A1 (tr)
WO (1) WO2001090106A2 (tr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260914T1 (de) * 2000-05-26 2004-03-15 Pfizer Triazolyltropanderivate als ccr5-modulatoren
KR20040007672A (ko) * 2001-06-12 2004-01-24 에스케이 주식회사 신규한 페닐알킬디아민 및 아미드 유사체
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
AU2003214503B2 (en) * 2002-04-08 2008-08-07 Pfizer Inc. Tropane derivatives as CCR5 modulators
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0208071D0 (en) * 2002-04-08 2002-05-22 Pfizer Ltd Tropane derivatives useful in therapy
WO2003100427A1 (en) * 2002-05-23 2003-12-04 Pfizer Limited Method for identification of a ligand whereby receptor residence time is measured
EP1569647B1 (en) * 2002-12-13 2008-08-20 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
SE0301369D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
DE10336274A1 (de) * 2003-08-07 2005-03-10 Honeywell Specialty Chemicals Verfahren zur Herstellung von geminalen Difluoralkanen
AR045536A1 (es) 2003-08-29 2005-11-02 Ranbaxy Lab Ltd Inhibidores de la fosfodiesterasa tipo -iv
EP1786816A4 (en) 2003-09-10 2009-11-04 Virochem Pharma Inc SPIROHYDANTOIN COMPOUNDS AND METHODS FOR MODULATING CHEMOKINE RECEPTOR ACTIVITY
AP2174A (en) * 2003-10-03 2010-11-20 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflamation.
TW200610761A (en) 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
AU2005251891A1 (en) 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-C] derivatives and their use as antiviral compounds
CA2586231A1 (en) * 2004-11-19 2006-05-26 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and uk-427, 857
WO2006064340A2 (en) * 2004-12-13 2006-06-22 Pfizer Limited Process for the preparation of n-acyl beta-aminoaldehydes
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
AU2006272750B2 (en) 2005-07-22 2011-09-29 Cytodyn, Inc. Methods for reducing viral load in HIV-1-infected patients
WO2007045573A1 (en) 2005-10-19 2007-04-26 F. Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
KR20090013827A (ko) * 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
KR101401811B1 (ko) 2006-08-16 2014-05-29 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 저해제
WO2008063600A2 (en) * 2006-11-17 2008-05-29 Concert Pharmaceuticals Inc. Triazolyl tropane derivatives
CA2671478C (en) 2006-12-13 2015-02-17 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
AU2007333667A1 (en) * 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preperation and utility of CCR5 inhibitors
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
WO2008132128A2 (en) * 2007-04-27 2008-11-06 Solvay (Société Anonyme) Synthesis of a pharmaceutically active compound
RU2368613C1 (ru) * 2008-02-19 2009-09-27 Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид
JP2011513317A (ja) * 2008-02-29 2011-04-28 シェーリング コーポレイション Ｈｉｖ感染を防止するための予防薬としてのｃｃｒ５アンタゴニストおよびｈｉｖの伝播を抑制する方法
CN101712679B (zh) * 2008-10-08 2013-04-10 中国科学院上海药物研究所 一种酰胺类化合物、其药物组合物及其制备方法和用途
WO2011011652A1 (en) * 2009-07-24 2011-01-27 Glaxosmithkline Llc Therapeutic compounds
CN102140104B (zh) * 2010-02-03 2014-11-12 中国科学院上海药物研究所 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途
CN102905698A (zh) 2010-04-02 2013-01-30 菲弗科－1有限责任公司 包含ccr5拮抗剂、hiv-1蛋白酶抑制剂和药代动力学增强剂的组合疗法
CN103159754A (zh) * 2011-12-19 2013-06-19 中国科学院上海药物研究所 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
CZ306455B6 (cs) 2013-04-26 2017-02-01 Zentiva, K.S. Nový způsob syntézy Maravirocu
CN103497164B (zh) * 2013-09-23 2015-12-23 西安近代化学研究所 一种蒽衍生物及其制备方法
CN104304248B (zh) * 2014-10-23 2016-08-10 西北农林科技大学 3-芳基丙酸酯类化合物作为制备杀螨药物的应用
CN104402883B (zh) * 2014-10-24 2016-04-27 艾琪康医药科技（上海）有限公司 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途
CN104387379B (zh) * 2014-11-26 2017-01-11 扬州氟药科技有限公司 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途
CN104860946A (zh) * 2015-05-14 2015-08-26 湖北生物医药产业技术研究院有限公司 Ccr5拮抗剂的制备方法
CN107879963A (zh) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2676444B1 (fr) * 1991-05-16 1995-03-10 Sanofi Elf Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant.
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
GEP19991749B (en) * 1994-04-19 1999-09-10 Neurosearch As Propane-2-Aldoxine Derivatives as Neurotransmitter Reuptake Inhibitors
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
WO1997024325A1 (en) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2259927A1 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025604A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
CA2296314A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
JP2002501052A (ja) * 1998-01-21 2002-01-15 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
EP1013276A1 (en) 1998-12-23 2000-06-28 Pfizer Inc. Aminoazacycloalkanes as CCR5 modulators
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) * 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
ATE260914T1 (de) * 2000-05-26 2004-03-15 Pfizer Triazolyltropanderivate als ccr5-modulatoren

Also Published As

Publication number Publication date
JP3693957B2 (ja) 2005-09-14
EG24137A (en) 2008-08-06
HU225810B1 (en) 2007-10-29
NO2010007I2 (no) 2013-09-09
PL359267A1 (en) 2004-08-23
EA005382B1 (ru) 2005-02-24
NL300338I2 (nl) 2008-06-02
AU2001252482C1 (en) 2001-12-03
DE122008000011I1 (de) 2008-06-05
ES2401812T3 (es) 2013-04-24
YU82202A (sh) 2005-11-28
GEP20063799B (en) 2006-04-25
HUP0302474A3 (en) 2007-05-29
KR20050046743A (ko) 2005-05-18
EP1526134A3 (en) 2006-11-29
CY2008006I2 (el) 2009-11-04
HK1090836A1 (en) 2007-01-05
NO327892B1 (no) 2009-10-12
DE60102233T2 (de) 2005-01-27
EP1990341A1 (en) 2008-11-12
IL152531A (en) 2010-05-17
AU5248201A (en) 2001-12-03
KR100523501B1 (ko) 2005-10-25
RS51436B (en) 2011-04-30
SI1526134T1 (sl) 2008-12-31
PT1284974E (pt) 2004-06-30
MY131019A (en) 2007-07-31
NO20025227D0 (no) 2002-10-31
EE05110B1 (et) 2008-12-15
CU23288B7 (es) 2008-06-30
BG65966B1 (bg) 2010-07-30
CN1437599A (zh) 2003-08-20
NO2010007I1 (no) 2010-04-08
CY1108451T1 (el) 2014-04-09
HRP20020938A2 (en) 2005-02-28
JP2003534343A (ja) 2003-11-18
CA2408909C (en) 2006-06-27
OA12264A (en) 2003-11-10
IS6565A (is) 2002-09-24
NO20025227L (no) 2002-10-31
HRP20020938B1 (en) 2011-05-31
LU91417I2 (fr) 2008-04-22
PL200551B1 (pl) 2009-01-30
CN1279040C (zh) 2006-10-11
BRPI0110955B1 (pt) 2016-06-28
TNSN01077A1 (fr) 2005-11-10
ME00555A (en) 2011-12-20
JP4854970B2 (ja) 2012-01-18
MXPA02011631A (es) 2003-03-27
CY2022009I2 (el) 2022-05-27
CR10145A (es) 2008-08-19
AU2001252482B2 (en) 2006-01-19
MY156920A (en) 2016-04-15
PE20011371A1 (es) 2002-01-18
EA007580B1 (ru) 2006-12-29
EP1284974B1 (en) 2004-03-03
KR100548854B1 (ko) 2006-02-02
PA8517101A1 (es) 2002-10-24
IS2511B (is) 2009-05-15
CN100355753C (zh) 2007-12-19
EA200401056A1 (ru) 2005-04-28
FR08C0007I2 (fr) 2009-01-15
WO2001090106A3 (en) 2002-03-28
ES2311126T3 (es) 2009-02-01
CZ299102B6 (cs) 2008-04-23
BR0110955A (pt) 2003-06-03
AP2002002663A0 (en) 2002-12-31
ATE260914T1 (de) 2004-03-15
CA2408909A1 (en) 2001-11-29
RS50904B (sr) 2010-08-31
HK1078573A1 (en) 2006-03-17
EP1990341B1 (en) 2013-01-23
AR028622A1 (es) 2003-05-14
DE60135685D1 (de) 2008-10-16
SK16432002A3 (sk) 2004-01-08
JP2005194283A (ja) 2005-07-21
NZ521477A (en) 2004-07-30
ES2215129T3 (es) 2004-10-01
MY153023A (en) 2014-12-31
FR08C0007I1 (tr) 2008-04-25
SI1284974T1 (en) 2004-08-31
BG107140A (bg) 2003-05-30
BRPI0110955B8 (pt) 2021-05-25
SK286129B6 (sk) 2008-04-07
DK1284974T3 (da) 2004-06-07
IL152531A0 (en) 2003-05-29
NL300338I1 (nl) 2008-05-01
UY26727A1 (es) 2001-12-28
AP1965A (en) 2009-03-04
HK1054927A1 (en) 2003-12-19
TWI230160B (en) 2005-04-01
CZ20023806A3 (cs) 2004-01-14
LU91417I9 (tr) 2019-01-02
DZ3464A1 (tr) 2001-11-29
DE60102233D1 (de) 2004-04-08
RS20090438A (en) 2010-05-07
EP1526134B1 (en) 2008-09-03
LTPA2008004I1 (lt) 2020-07-27
ME00555B (me) 2011-12-20
LTC1284974I2 (lt) 2020-11-10
CN1680371A (zh) 2005-10-12
MA26902A1 (fr) 2004-12-20
HUP0302474A2 (hu) 2003-11-28
AR060159A2 (es) 2008-05-28
KR20030004417A (ko) 2003-01-14
PT1526134E (pt) 2008-10-28
DK1526134T3 (da) 2008-11-17
CY2008006I1 (el) 2009-11-04
EA200201141A1 (ru) 2003-04-24
EP1284974A2 (en) 2003-02-26
CY2022009I1 (el) 2022-05-27
EP1526134A2 (en) 2005-04-27
NO2020019I1 (no) 2020-06-30
EE200200656A (et) 2004-06-15
ATE407134T1 (de) 2008-09-15
WO2001090106A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
TR200400541T4 (tr) Terapide faydalı tropan türevleri.
NO20025821L (no) 2-aminokarbonyl-9H-purinderivater
ATE302775T1 (de) Carbolinderivate
NO20034011L (no) Steroider som agonister for FXR
DK0862562T3 (da) Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
ATE346067T1 (de) Carbolinderivate
CY1107662T1 (el) Μεθοδος παρασκευης της (ε, ζ) 3-(2-aminoethoxyimino)-androstane-6,17-dione και αναλογων της
WO2005003087A3 (en) Oxazole derivatives as antibacterial agents
TR200101711T2 (tr) Antihistaminik spiro bileşikler.
NO20000737L (no) Tetrahydro &lt;gamma&gt;-karboliner
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
ATE330958T1 (de) Pyrazino 1&#39;2&#39;:1,6öpyrido 3,4-böindolderivate
ATE282608T1 (de) Chinoxalindionen
PL349933A1 (en) Novel compounds beta-hydroxyalylamides, method of obtaining them and their application
ECSP014089A (es) Derivados de tropano utiles en terapia
AP2001002179A0 (en) 2-Aminocarbonyl-9h-purine derivatives.
DK1065206T3 (da) Tetrazolylalkylindol-forbindelser som anti-inflammatoriske og analgetiske midler
MY120189A (en) Sultam and sultone derived oxazolidinones